In this Grand Rounds presentation, Memorial Sloan Kettering gastric surgeon Vivian Strong describes recent progress in staging, surgery, and minimally invasive treatment options for gastric cancer.
Memorial Sloan Kettering medical oncologist Yelena Janjigian discusses chemotherapy and other therapies undergoing clinical trial examination for gastric cancer.
Memorial Sloan Kettering surgical oncologist Daniel Coit reviews the progress and challenges ahead for gastric cancer surgery, medical therapy, and dissemination of MSK insights and techniques.
Medical oncologist David Ilson talks about advances in adjuvant therapies for gastric cancer in a Grand Rounds presentation.
Improvements in staging, advances in surgical technology, and enhanced appreciation for the heterogeneity of gastric cancer has led to significant progress in treating the disease. We have one of the nation’s highest surgical volumes for this cancer, performing approximately 100 gastrectomies annually (open and laparoscopic). Evidence indicates that our minimally invasive approach yields shorter hospital stays, decreased need for postoperative pain relief, and fewer postsurgical complications. Rates of recurrence-free survival at 36-month follow-up are similar to open surgery. We are one of the few NCI-designated cancer centers with a specific program in upper gastrointestinal tract cancers.